CORUM is a biotechnology company in Taiwan that is devoted to research, development and manufacture of cosmetic ingredients, API and pharmaceutical intermediates. The company has developed dozens of patented ingredients and applications. The company positions as an upstream supplier in the global beauty and pharmaceutical supply chain, providing a full range of products to customers across more than 30 countries.
To cope with the growing demand for cosmetic active ingredients and API, CORUM has been expanding its investments and resources in recent years. Today, CORUM announces that the company completed the production capacity expansion project at its plant in Chiayi, Taiwan at the end of November, 2021. Not only does this expansion increase production capacity for the manufacture of cosmetic active ingredients, APIs and pharmaceutical intermediates, it is also an important strategic move to accelerate the company’s global expansion.
With the completion of Chiayi Phase II plant, the annual production capacity of CORUM is expected to double. Under the trend of regionalization of the supply chain triggered by the epidemic, it can also deepen the niche in Asian market and establish a long-term competitive advantage.
The capacity expansion of Chiayi Plant fully introduced Hastelloy® pipelines, reaction tanks and other equipments to give more flexibility to the manufacturing process for its exceptional corrosion-resistant properties. In the future, we expect to produce more diversified products and expand our product portfolio. “The newly added cosmetic active ingredients and pharmaceutical intermediate production lines have already begun operations, driving growth of both Personal Care and Pharmaceutical business, with 2022 annual revenue expected to reach a new high.” said Mr. Pei-Min Lee, Chairman of CORUM.
“CORUM’s future strategy map will focus on the expansion of ingredient production capacity, continue to expand the ecosystem with existing strategic partners, target the development of new raw materials, and grow a deeper niche market.” Lee added.
With our latest investment in capacity expansion, the overall production process has also been thoroughly inspected to maximize efficiency and resilience, as well as to reduce carbon emissions and environmental impact.
Sustainable development has always been at the core of our thinking, leading us to integrate ESG into our business. Guided by Green Chemistry Principle # 1 (Waste Prevention) and # 12 (Inherently Safer Chemistry for Accident Prevention), our manufacturing process is optimized to increase safety and produce less waste. CORUM has been awarded as Occupational Safety and Health Excellent Unit by the Ministry of Labor for three consecutive years. This year, CORUM is awarded with Five Star Award as one of the top winners, making CORUM the first biotechnology company to win the award in Taiwan since its establishment.
We have made a lot of efforts to build an environmentally friendly plant in Chiayi. We have our own wastewater treatment plant and also build a long-term cooperation with waste recycling vendors in an ethical, safe and sustainable way to minimize environmental impacts as well as maximize recycling value.
With the current expansion plan completes, projections indicate that, our Scope 1 & Scope 2 CO2 emissions reductions per metric ton of production by 2025 would be around 18% lower compared to 2018 levels, to support the UN SDG 13 “Climate Action” and IEA's "Net Zero by 2050".
CORUM will continue to research, develop and provide innovative, high-quality and safe ingredients in science rigor, for a better solution to skin health and a world of caring, beauty and sustainability.
| Press Release
| Press Release